Pharmather Holdings Ltd. (OTCQB: PHRRF) reported financial results for its third quarter ended February 28, 2022.
Financial Results
Cash and cash equivalents totaled CA$10,165,170 ($7,955,803) and investment totaled CA$1,666,667 ($1,304,422) for a total of CA$11,831,837 ($9,260,226) as of February 28, 2022.
Accounts payable and accrued liabilities totaled CA$140,947 ($110,312) as of February 28, 2022.
Recent Highlights
The company received an Orphan Drug Designation for a ketamine-based medicine for treating an epileptic condition.
Received approval from the FDA to proceed with a Phase 2 clinical trial for an Amyotrophic Lateral Sclerosis treatment.
The company entered into collaborative research with Revive Therapeutics (OTCQB: RVVTF) to develop a psilocybin microneedle patch. Pharmather is also developing microneedle patches for administering ketamine (along with LTS Lohmann Therapie-Systeme AG) and another one for administering LSD.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.